A REVIEW ON BEDAQUILINE IN THE TREATMENT OF MULTI-DRUG-RESISTANT TUBERCULOSIS

Multidrug-resistant tuberculosis (MDR-TB) presents formidable treatment challenges, and tuberculosis (TB) continues to be a major global health concern. As the first medication created especially for tuberculosis in more than 40 years, bedaquiline, an antimicrobial agent based on the diarylquinoline class, marks a significant advancement in the treatment of tuberculosis. It interferes with Mycobacterium tuberculosis's energy metabolism by targeting ATP synthase. Bedaquiline, which was approved by the FDA in 2012, has demonstrated encouraging outcomes in treating MDR-TB, even in patients who are resistant to fluoroquinolones and other first-line treatments. Its distinct pharmacokinetics and structure, which include primary excretion through feces and high bioavailability with meals, increase its effectiveness and lessen cross-resistance. The significance of suitable companion medications is highlighted by the drug's vulnerability to resistance brought on by genetic mutations. QT interval prolongation and mild to moderate side effects are safety concerns prescribed as a component of combination therapy for patients with pulmonary MDR-TB who are older than 18.

• World Health Organization, Global Tuberculosis Report 2023 (Geneva, Switzerland: World Health Organization, 2023). Available from: https:// www. who. int/ teams/ globa l- tuber culos is- progr amme/ tb- reports
• A. Trajman, I. Felker, L. C. Alves, et al., “The COVID- 19 and TB Syndemic: The Way Forward,” International Journal of Tuberculosis and Lung Disease, 2022; 26(8): 710–719. 
• Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005; 307: 223–227. 
• World Health Organization. The use of bedaquiline in the treatment of multidrug-resistant tuberculosis. Interim policy guidance (WHO/HTM/TB/2013.6). http://apps.who.int/iris/bitstream/10665/84879/1/9789241505482_eng. pdf Date last accessed: May 5, 2015.
• Diacon AH, Pym A, Grobusch MP, et al. Multidrug-resistant tuberculosis and culture conversion with bedaquiline. N Engl J Med, 2014; 371: 723–732.
• Tiberi S, De Lorenzo S, Centis R, et al. Bedaquiline in MDR/XDR-TB cases: first experience on compassionate use. Eur Respir J, 2014; 43: 289–292.
• Guglielmetti L, Le Dû D, Jachym M, et al. Compassionate use of bedaquiline for the treatment ofmultidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort. Clin Infect Dis., 2015; 60: 188–194.
• Udwadia ZF, Amale RA, Mullerpattan JB. Initial experience of bedaquiline uses in a series of drug-resistanttuberculosis patients from India. Int J Tuberc Lung Dis., 2014; 18: 1315–1318.
• Ndjeka N, Conradie F, Schnippel K, et al. Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis. Int J Tuberc Lung Dis., 2015; 19: 979–985.
• Diacon AH, Pym A, Grobusch MP, et al. The diarylquinoline bedaquiline for multidrug-resistant tuberculosis. N Engl J Med., 2009; 360: 2397–2405.
• Diacon AH, Donald PR, Pym A, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatmentfor multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother, 2012; 56: 3271–3276.
• World Health Organization. Global tuberculosis report 2024. Geneva: World Health Organization, 2024.
• He W, Tan Y, Song Z, Liu B, Wang Y, He P, et al. Endogenous relapse and exogenous reinfection in recurrent pulmonary tuberculosis: a retrospective study revealed by whole genome sequencing. Front Microbiol, 2023; 14: 1115295. 
• Oelemann MC, Diel R, Vatin V, Haas W, Rüsch-Gerdes S, Locht C, et al. Assessment of an optimized mycobacterial interspersed repetitive-unit-variable-number tandem- repeat typing system combined with spoligotyping for population-based molecular epidemiology studies of tuberculosis. J Clin Microbiol, 2007; 45(3): 691–7. 
• Conradie F, Diacon AH, Ngubane N, Howell P, Everitt D, Crook AM, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med, 2020; 382(10): 893–902.
• Nyang’wa BT, Berry C, Kazounis E, Motta I, Parpieva N, Tigay Z, et al. A 24-week, all-oral regimen for rifampin-resistant tuberculosis. N Engl J Med, 2022; 387(25): 2331–43. 
• Conradie F, Bagdasaryan TR, Borisov S, Howell P, Mikiashvili L, Ngubane N, et al. Bedaquiline–pretomanid–linezolid regimens for drug-resistant tuberculosis. N Engl J Med., 2022; 387(9): 810–23.
• Padmapriyadarsini C, Vohra V, Bhatnagar A, Solanki R, Sridhar R, Anande L, et al. Bedaquiline, delamanid, linezolid, and clofazimine for treatment of pre-extensively drug-resistant tuberculosis. Clin Infect Dis., 2023; 76(3): e938–46.
• Ndjeka N, Campbell JR, Meintjes G, Maartens G, Schaaf HS, Hughes J, et al. Treatment outcomes 24 months after initiating short, all-oral bedaquiline-containing or injectable-containing rifampicin-resistant tuberculosis treatment regimens in South Africa: a retrospective cohort study. Lancet Infect Dis., 2022; 22(7): 1042–51.
• Alemu A, Bitew ZW, Worku T. Poor treatment outcome and its predictors among drug-resistant tuberculosis patients in Ethiopia: a systematic review and meta- analysis. Int J Infect Dis., 2020; 98: 420–39.
• Imperial MZ, Nedelman JR, Conradie F, Savic RM. Proposed linezolid dosing stra tegies to minimize adverse events for treatment of extensively drug-resistant tu berculosis. Clin Infect Dis., 2022; 74(10): 1736–47.
• Matteelli A, Carvalho AC, Dooley KE, Kritski A. TMC207: the first compound of a new class of potent anti-tuberculosis drugs. Future Microbiol, 2010; 5: 849-58.
• Andries K, Verhasselt P, Guillemont J. E. G, Gohlmann HW. Neefs JM, Winkler H, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science, 2005; 307: 223-7. 
• Gumbo T. TMC-207 (R207910). In: Bruten L, Chabner BA, Knollmann BC, editors. Goodman and Gillman’s The Pharmacological Basis of Therapeutics. 12th edn. New York, NY: McGraw Hill Companies, 2011: 1561. 
• Ahmad S. New Perspectives in the Diagnosis and Treatment of Tuberculosis. J Bacteriol Parasitol, 2012; 3: e114. doi:10.4172/2155-9597.1000e114. 
• Van Heeswijk, R, Lachaert R, Leopold L, DeBeule K, McNeeley D. The effect of CYP3A4 inhibition on the clinical pharmacokinetics of TMC207. Presented at: the 38th Union World Conference on Lung Health; Cape Town, South Africa. 8-12 November, 2007; Poster PS-71358-71311.
• Huitric E, Verhasselt P, Andries K, Hoffner SE. In vitro antimycobacterial spectrum of a diarylquinoline ATP-synthase inhibitor. Antimicrob Agents Chemother, 2007; 51: 4202-4.
• Shi L, Sohaskey CD, Kana BD, Dawes S, North RJ, Mizrahi V, et al. Changes in energy metabolism of Mycobacterium tuberculosis in mouse lung and in vitro conditions affecting aerobic respiration. Proc Natl Acad Sci U S A, 2005; 102: 15629-34. 
• Koul A, Vranckx L, Dendouga N, Balemans W, Van den Wyngaert I, Vergauwen K, et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem., 2008; 283: 25273-80. 
• Kim J. H., Lee H., Oh I. S., et al., “Comparative Safety of Bedaquiline and Delamanid in Patients with Multidrug Resistant Tuberculosis: A Nationwide Retrospective Cohort Study,” Journal of Microbiology, Immunology, and Infection, 2023; 56(4): 842–852. [DOI] [PubMed] [Google Scholar]
• Fujiwara M., Kawasaki M., Hariguchi N., Liu Y., and Matsumoto M., “Mechanisms of Resistance to Delamanid, a Drug for Mycobacterium tuberculosis,” Tuberculosis, 2018; 108: 186–194. [DOI] [PubMed] [Google Scholar]
• Liu Y., Matsumoto M., Ishida H., et al., “Delamanid: From Discovery to Its Use for Pulmonary Multidrug‐Resistant Tuberculosis (MDR‐TB),” Tuberculosis (Edinburgh, Scotland), 2018; 111:     20–30. [DOI] [PubMed] [Google Scholar]
• Dooley K. E., Rosenkranz S. L., Conradie F., et al., “QT Effects of Bedaquiline, Delamanid, or Both in Patients with Rifampicin‐Resistant Tuberculosis: A Phase 2, Open‐Label, Randomised, Controlled Trial,” Lancet Infectious Diseases, 2021; 21(7): 975–983. [DOI] [PMC free article] [PubMed] [Google Scholar]
• Tadolini M., Lingtsang R. D., Tiberi S., et al., “First Case of Extensively Drug‐Resistant Tuberculosis Treated with Both Delamanid and Bedaquiline,” European Respiratory Journal, 2016; 48: 935–938. [DOI] [PMC free article] [PubMed] [Google Scholar]
• Maryandyshev A., Pontali E., Tiberi S., et al., “Bedaquiline and Delamanid Combination Treatment of 5 Patients with Pulmonary Extensively Drug‐Resistant Tuberculosis,” Emerging Infectious Diseases, 2017; 23: 1718–1721. [DOI] [PMC free article] [PubMed] [Google Scholar]
• Ferlazzo G., Mohr E., Laxmeshwar C., et al., “Early Safety and Efficacy of the Combination of Bedaquiline and Delamanid for the Treatment of Patients with Drug‐Resistant Tuberculosis in Armenia, India, and South Africa: A Retrospective Cohort Study,” Lancet Infectious Diseases, 2018; 18: 536–544. [DOI] [PubMed] [Google Scholar]
• Lu P., Characterization of antibacterial drugs and drug combinations targeting oxidative phosphorylation in Mycobacteria. [PhD‐Thesis–Research and graduation internal, Vrije Universiteit Amsterdam] 2015. Available from: https://research.vu.nl/ws/portalfiles/portal/42149192/chapter+4.pdf.
• Irwin S. M., Prideaux B., Lyon E. R., et al., “Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice,” ACS Infectious Diseases, 2016; 2(4): 251–267. [DOI] [PMC free article] [PubMed] [Google Scholar]
• Diacon A. H., Dawson R., von Groote‐Bidlingmaier F., et al., “14‐Day Bactericidal Activity of PA‐824, Bedaquiline, Pyrazinamide, and Moxifloxacin Combinations: A Randomised Trial,” Lancet, 2012; 380: 986–993. [DOI] [PubMed] [Google Scholar]
• Occhineri S., Matucci T., Rindi L., et al., “Pretomanid for Tuberculosis Treatment: An Update for Clinical Purposes,” Current Research in Pharmacology and Drug Discovery, 2022; 3: 100128, 10.1016/j.crphar.2022.100128. [DOI] [PMC free article] [PubMed] [Google Scholar]
• Shirley M., “Pretomanid in Drug‐Resistant Tuberculosis: A Profile of Its Use,” Drugs & Therapy Perspectives, 2020; 36: 273–279. [Google Scholar]
• Wallis R. S., Jakubiec W., Mitton‐Fry M., et al., “Rapid Evaluation in Whole Blood Culture of Regimens for XDR‐TB Containing PNU‐100480 (Sutezolid), TMC207, PA‐824, SQ109, and Pyrazinamide,” PLoS One, 2012; 7(1): e30479. [DOI] [PMC free article] [PubMed] [Google Scholar]
• Tasneen R., Williams K., Amoabeng O., et al., “Contribution of the Nitroimidazoles PA‐824 and TBA‐354 to the Activity of Novel Regimens in Murine Models of Tuberculosis,” Antimicrobial Agents and Chemotherapy, 2015; 59(1): 129–135. [DOI] [PMC free article] [PubMed] [Google Scholar]
• Tasneen R., Betoudji F., Tyagi S., et al., “Contribution of Oxazolidinones to the Efficacy of Novel Regimens Containing Bedaquiline and Pretomanid in a Mouse Model of Tuberculosis,” Antimicrobial Agents and Chemotherapy, 2016; 60(1): 270–277. [DOI] [PMC free article] [PubMed] [Google Scholar]
• Xu J., Li S. Y., Almeida D. V., et al., “Contribution of Pretomanid to Novel Regimens Containing Bedaquiline with Either Linezolid or Moxifloxacin and Pyrazinamide in Murine Models of Tuberculosis,” Antimicrobial Agents and Chemotherapy, 2019; 63(5): e00021‐19. [DOI] [PMC free article] 
• Lyons M. A., “Pretomanid Dose Selection for Pulmonary Tuberculosis: An Application of Multi‐Objective Optimization to Dosage Regimen Design,” CPT: Pharmacometrics & Systems Pharmacology, 2021; 10(3): 211–219. [DOI] [PMC free article] [PubMed] [Google Scholar]
• Saderi L., Puci M., Di Lorenzo B., et al., “Rapid Diagnosis of XDR and Pre‐XDR TB: A Systematic Review of Available Tools,” Archivos de Bronconeumología, 2022; 58(12): 809–820. [DOI] [PubMed] [Google Scholar]
• [PubMed] [Google Scholar]
• Matteelli A, Carvalho AC, Dooley KE, Kritski A. TMC207: the first compound of a new cl Gumbo T. TMC-207 (R207910). In: Bruten L, Chabner BA, Knollmann BC, editors. Goodman and Gillman’s The Pharmacological Basis of Therapeutics. 12th edn. New York, NY: McGraw Hill Companies, 2011: 1561.
• Huitric E, Verhasselt P, Andries K, Hoffner SE. In vitro antimycobacterial spectrum of a diarylquinoline ATP-synthase inhibitor. Antimicrob Agents Chemother, 2007; 51: 4202-4.
• Petrella S, Cambau E, Chauffour A, Andries K, Jarlier V, Sougakoff W. Genetic basis for natural and acquired resistance of the diaryquinoline. R207910 in mycobacteria. Antimicrob Agents Chemother, 2006; 50: 2853-6. 
• Sirturo (bedaquiline fumarate). Available at http://dailymed.nlm.nih.gov/dailymed/ lookup.cfm?setid=1534c9ae-4948-4cf4-9f66 222a99db6d0e.pdf. Accessed 20 Jan 2013. 
• Bedaquiline. Available at http://reference.medscape.com/drug/sirturo bedaquiline-999799#5. Accessed 20 Jan 2013.
• Diacon AH, Pym AP, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med., 2009; 360: 2397-405.
• Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, et al. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother, 2012; 56: 3271-6. 
• Guglielmetti L, Khan U, Velásquez GE, et al. Nine-month, all-oral regimens for rifampin-resistant tuberculosis. medRxiv 2024; preprint [10.1101/2024.01.29.24301679]. [DOI] [Google Scholar]
• Muniyandi M, Karikalan N, Velayutham B, et al. Cost effectiveness of a shorter moxifloxacin-based regimen for treating drug sensitive tuberculosis in India. Trop Med Infect Dis., 2022; 7: 288. doi: 10.3390/tropicalmed7100288 [DOI] [PMC free article] [PubMed] [Google Scholar]
• Kohler S, Sitali N, Achar J, et al. Programme costs of longer and shorter tuberculosis drug regimens and drug import: a modelling study for Karakalpakstan, Uzbekistan. ERJ Open Res., 2022; 8: 00622-2021. doi: 10.1183/23120541.00622-2021 [DOI] [PMC free article] [PubMed] [Google Scholar]
• Kohler S, Sitali N, Achar J, et al. Costs and import costs of past, present, and future TB drug regimens: a case study for Karakalpakstan, Uzbekistan. J Public Health, 2023; 45: 481–487. doi: 10.1093/pubmed/fdac124 [DOI] [PubMed] [Google Scholar]
• Mulder C, Rupert S, Setiawan E, et al. Budgetary impact of using BPaL for treating extensively drug-resistant tuberculosis. BMJ Glob Health, 2022; 7: e007182. doi: 10.1136/bmjgh-2021-007182 [DOI] [PMC free article] [PubMed] [Google Scholar]
• Muniyandi M, Ramesh PM, Wells WA, et al. The cost-effectiveness of the BEAT-TB regimen for pre-extensively drug-resistant TB. Trop Med Infect Dis., 2023; 8: 411. doi: 10.3390/tropicalmed8080411 [DOI] [PMC free article] [PubMed] [Google Scholar]